Results of a retrospective review assessing the prevalence of chronic opioid use among patients with oropharynx cancer after surgery was presented at the 2018 American Head & Neck Society Annual Meeting.
Aggressive de-escalation of chemoradiation after surgery in patients with HPV-associated OPSCC led to similar disease control and improved quality of life and safety profile compared with historical controls, according to data presented at the ASTRO 59th Annual Meeting.
Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Disease-specific survivorship care plans (SCPs) for head and neck cancer support a successful transition to a healthy lifestyle after curative intent therapy of larynx and oral cavity/pharynx cancer.
A literature review noted improvements in quality of life after patients were coached and educated following radiotherapy for HPV-associated oropharyngeal cancers.
Clinical practice guideline from ASTRO addresses optimal radiation doses and fractionation schedules, integrating therapies, and induction chemotherapy for oropharyngeal squamous cell carcinoma (OPSCC).
Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
The impact of oral squamous cell carcinoma (OSCC) diagnosis and treatment on sexual behavior and relationship stress with respect to HPV status was evaluated in this study. Participants included patients with HPV-positive and HPV-negative disease, as well as partners.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Transoral robotic surgery (TORS) with or without radiation therapy or chemotherapy is an effective treatment option for patients with oropharyngeal cancer regardless of their p16 status.
